Precision Therapeutics (NSDQ:AIPT) CEO Carl Schwartz recently boosted his stake in the company by $1.37 million, including a $950,000 loan and the $50,000 purchase of 78,125 shares of the company’s common stock, representing a price of $0.64 per share. As part of the investment, detailed this week in an SEC filing, Schwartz also received additional […]
Helomics
Precision Therapeutics to acquire Helomics
Precision Therapeutics (NSDQ:AIPT) said today it inked a letter of intent to acquire the remaining equity in Helomics, making it a wholly owned subsidiary. Minneapolis, Minn.-based Precision Therapeutics, which currently owns 25% of Helomics, said that it will acquire the remaining 75% equity stake in the company. Precision Therapeutics said it is hopeful that a new […]
Skyline Medical to take 20% stake in Helomics, license Illumina’s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which […]
7 medtech stories we missed this week: Nov. 17, 2017
From Skyline Medical’s joint venture to Lensar receiving FDA clearance and CE Mark, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Skyline Medical launches JV deal with Helomics Skyline Medical announced in a Nov. 15 press release that it has signed a joint venture agreement with Helomics. […]
7 medtech stories we missed this week: Nov. 3, 2017
From Hologic’s new product launch to CapsoVision gettting CE Mark approval, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Hologic launches new MyoSure device Hologic announced in a Nov. 1 press release that it has launched its MyoSure Manual Device in the U.S. The device is designed […]